Form 4: Passage BIO Director Acquires Stock Options

Passage BIO, Inc. reports that Director Sandip Kapadia acquired stock options on May 19, 2026, as detailed in a Form 4 filing.

Summary

• Director Sandip Kapadia acquired 10,539 stock options for Passage BIO, Inc. (PASG) on May 19, 2026.
• The stock options have an exercise price of $5.08 and are exercisable starting May 19, 2036.
• These options represent the right to buy 10,539 shares of common stock.
• The options vest in full on the earlier of the one-year anniversary of the grant date or the date of the issuer's 2027 Annual Meeting, contingent on Kapadia's continuous service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard grant of stock options to a director, which is typical compensation and not necessarily indicative of a significant change in the company's prospects.

Positives

• Director Sandip Kapadia's acquisition of stock options indicates a commitment to the company's future performance.
• The vesting schedule aligns with continued service, incentivizing long-term engagement.

Risks

• The value of the stock options is subject to the future performance of Passage BIO's stock price.
• The vesting is contingent on continuous service, meaning any departure before the vesting date would result in forfeiture of the options.

Future Outlook

The future outlook for the acquired stock options is dependent on the company's performance and the stock price, with vesting contingent on continued service and the company's 2027 Annual Meeting.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into the holdings and activities of company directors and officers. This particular filing indicates a director's acquisition of equity-based compensation, a common practice in the biotechnology sector to align executive interests with shareholder value.

Stakeholder Impact

• Shareholders: The acquisition of options by a director can be seen as a positive signal of confidence in the company's long-term prospects, potentially aligning director interests with those of shareholders.
• Employees: The vesting schedule tied to continuous service reinforces the importance of employee retention and performance.
• Management: The grant of options is a standard form of executive compensation, incentivizing performance and long-term commitment.

Next Steps

• Director Kapadia must maintain continuous service to Passage BIO to ensure the vesting of the stock options.
• The company's stock performance will determine the ultimate value of the acquired options.

Key Dates

Keywords

Form 4, SEC Filing, Stock Options, Insider Trading, Passage BIO, PASG, Director, Beneficial Ownership, Securities Exchange Act